Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.54 |
| ▸ | BTK | Q06187 | 7/20 | 0.53 |
| ▸ | EGFR | P00533 | 5/20 | 0.52 |
| ▸ | INSR | P06213 | 2/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 8/20 | 0.52 |
| ▸ | JAK1 | P23458 | 3/20 | 0.48 |
| ▸ | TYK2 | P29597 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18001623 | 0.91 | FGFR2 (0.55) | JAK2FGFR2BTKEGFRJAK3 | |
| SCHEMBL18001119 | 0.90 | FGFR2 (0.54) | JAK2FGFR2BTKEGFRJAK3 | |
| SCHEMBL18001439 | 0.89 | FGFR2 (0.68) | JAK2FGFR2BTKEGFRINSR | |
| SCHEMBL18000936 | 0.89 | ALK (0.67) | JAK2BTKEGFRINSRALK | |
| SCHEMBL18001997 | 0.88 | FGFR2 (0.56) | JAK2FGFR2BTKEGFRINSR | |
| SCHEMBL18001871 | 0.86 | INSR (0.67) | JAK2BTKEGFRINSRALK | |
| SCHEMBL18000636 | 0.86 | FGFR1 (0.56) | JAK2FGFR2BTKEGFRALK | |
| SCHEMBL18001813 | 0.85 | BTK (0.49) | JAK2FGFR2BTKEGFRJAK3 | |
| SCHEMBL521054 | 0.84 | ALK (0.58) | JAK2INSRALKPTK2 | |
| SCHEMBL16513850 | 0.81 | FGFR2 (0.80) | JAK2FGFR2BTKEGFRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163423-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-06-03 | — | — | US | claimed |
| EP-3270694-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2018-01-24 | — | — | EP | claimed |
| US-20160304471-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2016-10-20 | — | — | US | claimed |
| WO-2016133935-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2016-08-25 | — | — | WO | claimed |
| US-20210163423-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| US-10947201-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3270694-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2018-01-24 | — | — | EP | disclosed |
| US-20160304471-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2016-10-20 | — | — | US | disclosed |
| WO-2016133935-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163423-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | JAK2 53/4885FGFR2 365/4885BTK 172/4885 |
| US-10947201-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | JAK2 53/4885FGFR2 365/4885BTK 172/4885 |
| US-20160304471-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | JAK2 53/4885FGFR2 365/4885BTK 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.